Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development
- PMID: 36295535
- PMCID: PMC9611876
- DOI: 10.3390/medicina58101374
Biomarkers in Alzheimer Disease and Other Dementias: What's Next into Pathophysiology to Support Clinical Practice and Drug Development
Abstract
Neurodegenerative diseases are a heterogeneous group of disorders characterized by gradual progressive neuronal loss in the central nervous system [...].
Conflict of interest statement
The author declares no conflict of interest.
Similar articles
-
Value-Generating Exploratory Trials in Neurodegenerative Dementias.Neurology. 2021 May 18;96(20):944-954. doi: 10.1212/WNL.0000000000011774. Epub 2021 Mar 5. Neurology. 2021. PMID: 33674360 Free PMC article. Review.
-
Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking?Neurobiol Aging. 2002 Jul-Aug;23(4):517-9; discussion 521-2. doi: 10.1016/s0197-4580(01)00349-9. Neurobiol Aging. 2002. PMID: 12009499 No abstract available.
-
What's hot, what's not, in dementia drugs? Part I: Cholinergic therapies.J Gerontol Nurs. 1997 Sep;23(9):52-4. doi: 10.3928/0098-9134-19970901-12. J Gerontol Nurs. 1997. PMID: 9355485 No abstract available.
-
Nonsteroidal anti-inflammatory drugs and Alzheimer disease: what's next?JAMA. 2003 Jun 4;289(21):2865-7. doi: 10.1001/jama.289.21.2865. JAMA. 2003. PMID: 12783919 No abstract available.
-
An Overview of Primary Dementias as Clinicopathological Entities.Semin Neurol. 2019 Apr;39(2):153-166. doi: 10.1055/s-0039-1683445. Epub 2019 Mar 29. Semin Neurol. 2019. PMID: 30925609 Review.
References
-
- Bougea A. Synuclein in neurodegeneration. Adv. Clin. Chem. 2021;103:97–134. - PubMed
-
- Magdalinou N.K., Paterson R.W., Schott J.M., Fox N.C., Mummery C., Blennow K., Bhatia K., Morris H.R., Giunti P., Warner T.T., et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J. Neurol. Neurosurg. Psychiatry. 2015;86:1240–1247. doi: 10.1136/jnnp-2014-309562. - DOI - PMC - PubMed
-
- Scarmeas N., Daskalaki A., Kalligerou F., Ntanasi E., Mamalaki E., Gargalionis A.N., Patas K., Chatzipanagiotou S., Yannakoulia M., Constantinides V.C. Initial Data and a Clinical Diagnosis Transition for the Aiginition Longitudinal Biomarker Investigation of Neurodegeneration (ALBION) Study. Medicina. 2022;58:1179. doi: 10.3390/medicina58091179. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical